In Section C, participants will obtain ABBV-744 and oral navitoclax. In Section D, individuals will acquire ABBV-744 and ruxolitinib. Members will get treatment until finally disorder progression or the contributors are not able to tolerate the study drugs. In general, our recent work highlights the potential utilization of ARV-825 in https://abbv-744-brd4-inhibitor-c13467.goabroadblog.com/31295208/what-does-new-advancements-in-brd4-inhibition-therapy-abbv-744-mean